Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Fulcrum Therapeutics is a clinical-stage biotechnology company focused on genetically defined rare diseases, with its lead commercial asset losmapimod approved for facioscapulohumeral muscular dystrophy (FSHD) and pipeline candidates targeting sickle cell disease and other genetic disorders. The company's DUX4 inhibition platform for FSHD represents a differentiated mechanism in a rare disease market with limited treatment options. Recent explosive revenue growth reflects commercial launch dynamics, though the company remains cash-consumptive with negative operating margins typical of early-stage biotech commercialization.
Fulcrum generates revenue through specialty pharmaceutical sales of losmapimod to FSHD patients, leveraging orphan drug pricing dynamics in a genetically defined rare disease population of approximately 16,000-38,000 diagnosed patients in the US. The company employs a targeted commercial strategy using specialty distributors and patient access programs, typical for rare disease launches. Pricing power derives from orphan drug exclusivity, lack of approved alternatives for FSHD, and payer willingness to cover treatments for debilitating genetic conditions. Gross margins of 21% reflect early-stage manufacturing scale and distribution costs, with significant improvement potential as volumes increase. The business model depends on successful market penetration in a small patient population, requiring high per-patient revenue to achieve profitability.
Losmapimod commercial uptake metrics: new patient starts, persistence rates, and quarterly prescription volume trends in FSHD population
Clinical trial readouts for pipeline assets, particularly FTX-6058 (sickle cell disease) Phase 2 data and any new program initiations
Regulatory milestones including potential label expansions, international approvals for losmapimod, or IND filings for early-stage candidates
Cash runway extensions through financing events, partnerships, or milestone payments that affect dilution risk and operational continuity
Competitive developments in FSHD treatment landscape or alternative DUX4 inhibition approaches from larger pharma competitors
Rare disease market size constraints: FSHD addressable population of 16,000-38,000 US patients creates revenue ceiling that may limit losmapimod peak sales to $300-500M range even at high penetration, requiring successful pipeline diversification for growth
Regulatory and reimbursement evolution for high-cost genetic therapies: increasing payer scrutiny of orphan drug pricing and potential legislative action on specialty pharmaceutical costs could compress margins or limit pricing flexibility
Clinical development risk concentration: pipeline heavily weighted toward genetic diseases with complex pathophysiology, where clinical trial failure rates exceed 90% and proof-of-concept requires expensive, lengthy studies
Emerging FSHD competition from well-capitalized pharma developing alternative DUX4 inhibitors, gene therapies, or myostatin inhibitors that could erode losmapimod market share or force pricing concessions
Sickle cell disease pipeline faces intense competition from approved gene therapies (Casgevy, Lyfgenia) and competitive programs from Pfizer, Novartis, and other large-cap pharma with superior resources and commercialization capabilities
Limited commercial infrastructure and rare disease expertise versus established specialty pharma competitors with deeper payer relationships and patient access programs
Cash consumption risk: negative operating cash flow and -0.4% FCF yield indicate ongoing capital requirements, with current burn rate likely requiring additional financing within 12-18 months absent significant revenue acceleration
Equity dilution risk from future capital raises: pre-profitable biotech with $600M market cap faces substantial dilution risk if forced to raise capital at unfavorable valuations during market downturns or clinical setbacks
Revenue concentration: heavy dependence on single commercial product (losmapimod) creates binary risk if safety issues, competitive displacement, or reimbursement challenges emerge
low - Rare disease treatments demonstrate minimal correlation to GDP cycles as patients with debilitating genetic conditions require therapy regardless of economic conditions. FSHD is a progressive muscular dystrophy where treatment decisions are driven by medical necessity rather than discretionary spending. However, severe recessions could pressure payer reimbursement policies or patient out-of-pocket affordability for high-cost specialty drugs. The 2,752% revenue growth reflects product launch dynamics rather than economic sensitivity.
Rising interest rates create moderate headwinds through two channels: (1) Higher discount rates compress NPV of future cash flows for pre-profitable biotech, disproportionately affecting valuation multiples for companies trading on long-term pipeline value rather than current earnings. (2) Increased financing costs for future capital raises, though current 17.7x current ratio suggests near-term liquidity is adequate. The 4% debt-to-equity ratio indicates minimal direct interest expense impact. Rate environment primarily affects equity valuation and cost of capital for future dilutive financings rather than operational economics.
Minimal direct credit exposure given asset-light business model and strong current ratio of 17.7x. The company operates through specialty pharmaceutical distributors with standard payment terms, limiting accounts receivable risk. Primary credit consideration is access to capital markets for future financing needs, where tightening credit conditions could increase dilution costs or limit runway extension options. High-yield credit spreads serve as proxy for risk appetite in growth equity markets that fund clinical-stage biotech.
growth - Attracts speculative biotech investors focused on clinical catalysts, rare disease commercial opportunity, and pipeline optionality rather than current profitability. The 182.8% one-year return and 60.5% six-month return reflect momentum-driven trading around clinical milestones and commercial launch dynamics. Negative margins and cash consumption preclude value or income investors. Typical holders include healthcare-focused hedge funds, biotech specialists, and retail investors seeking high-risk/high-reward exposure to rare disease therapeutics with near-term catalysts.
high - Clinical-stage biotech with binary event risk from trial readouts, regulatory decisions, and financing events. Small $600M market cap amplifies price swings on modest volume. Recent 182.8% annual return demonstrates extreme volatility characteristic of early commercial-stage rare disease companies. Implied beta likely 1.5-2.0x relative to biotech indices, with intraday moves of 10-20% common around data releases or capital markets activity. Volatility elevated by cash consumption concerns and single-product revenue concentration.
